PTAB Denies Institution on Biogen’s Tysabri® Patent

PTAB + IPR

On October 17, the PTAB denied institution of IPR2016-000912, IPR2016-00915, IPR2016-00916.  The Petitions in these cases were filed by Swiss Pharma International AG on U.S. Patent Nos. 8,815,236; 8,349,321; and 8,900,577, respectively, all owned by Biogen.  The patents all relate to compositions of natalizumab, marketed by Biogen under the brand-name Tysabri®.  The documents denying institution and other important PTAB documents are filed in our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.